Jason Faris

Company: Novartis AG

Job title: Senior CPL

Seminars:

Panel Discussion: An Overview of the Hippo Pathway Drug Development Landscape 9:00 am

What indications are showing most promise for therapeutic intervention on the Hippo pathway? Will targeted approaches on TEAD isoforms be the key to navigating risk of toxicity from pan-TEADs? How do we convince investors Hippo pathway treatments are worth their time when some consider the pathway ‘unvalidated’? What are the advantages/risks in targeting YAP/TAZ and…Read more

day: Conference Day One

IAG933, a selective YAP1/TAZ-panTEAD PPI inhibitor 10:15 am

The development and characterization of a direct pan-TEAD PPI inhibitor, IAG933 Preclinical data supporting efficacy with IAG933 Discovery of promising targeted therapy combinations with IAG933Read more

day: Conference Day One